Comparison
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
A metabolic disorder affecting the body's ability to produce energy from fats. Episodes of low blood sugar, vomiting, and metabolic crisis can occur, especially during fasting or illness. Dietary management and emergency protocols are essential.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
0-6
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-hydroxy-3-methylglutaryl-coa-synthase-deficiency-C2751532 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Metabolic crisis | Vomiting, lethargy, and low blood glucose may occur with fasting or illness. | Acute metabolic decompensation is not a described core feature. | High |
| Development | Development may be affected after severe crises; baseline delay is not established. | Developmental delay and learning or behavioral concerns may be present. | Moderate |
| Physical features | No characteristic congenital appearance is established. | Variable physical features may occur, but findings are not specific. | Moderate |
When to favor each condition
Choose 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 when
Recurrent illness- or fasting-related hypoglycemia
This pattern fits impaired hepatic ketone production more than a chromosomal syndrome.
High
Unexplained metabolic acidosis with low ketones
Suggests a fatty-acid or ketogenesis disorder requiring specialist testing.
Moderate
Family history consistent with autosomal recessive disease
Supports consideration of HMG-CoA synthase deficiency, but confirmation is required.
Moderate
Choose 17q11 2 Microduplication Syndrome C3495679 when
Developmental delay with dysmorphic or growth findings
A chromosomal microarray is more relevant than metabolic crisis testing alone.
Moderate
Behavioral concerns without metabolic decompensation
Fits the described congenital syndrome better than ketogenesis deficiency.
Moderate
Known 17q11.2 duplication on genetic testing
A confirmed duplication supports this diagnosis over a metabolic enzyme disorder.
High
How key tests differ
| Test | 3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Metabolic studies during illness | Hypoketotic hypoglycemia or related abnormalities may be found; cutoffs are not fixed here. | No characteristic acute metabolic pattern is established. | Abnormal results suggest, but do not alone diagnose, the enzyme deficiency. |
| Enzyme or gene testing | HMGCS2-related testing may confirm the metabolic diagnosis. | Not expected to identify the chromosomal duplication. | Use targeted testing rather than treating either result as interchangeable. |
| Chromosomal microarray | No 17q11.2 duplication is expected from this metabolic disorder. | May detect the microduplication; clinical correlation remains necessary. | A copy-number result requires clinician interpretation and is distinct from an enzyme defect. |
Prognosis comparison
3 Hydroxy 3 Methylglutaryl Coa Synthase Deficiency C2751532
- Outcome
- Potentially serious but may improve with avoidance of triggers and specialist care; exact outcomes are not established here.
- Factors
- Crisis severity, fasting, intercurrent illness, and timeliness of treatment.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Generally chronic and moderate, with variable developmental and behavioral needs.
- Factors
- Duplication size, associated findings, and access to early intervention.
Time frame: Both are long-term conditions; metabolic risk is episodic, while developmental needs are ongoing.
Individual genetics, complications, and supportive care determine course.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute decompensation | Fasting or illness may precipitate vomiting, hypoglycemia, and metabolic crisis. This complication is not established as typical. Emergency protocols are central for the metabolic disorder. |
| Neurodevelopment | Injury risk relates mainly to severe or recurrent crises. Developmental and behavioral difficulties may be ongoing. Causes and supports differ; outcomes are variable. |
| Associated congenital issues | No specific congenital malformation pattern is established. Variable physical or medical features may require evaluation. Do not assume a uniform complication profile. |
Patient education highlights
- HighIllness precautions
For suspected HMG-CoA synthase deficiency, avoid prolonged fasting and use the clinician’s emergency plan during illness.
- HighDifferent conditions
These are unrelated disorders; a metabolic crisis plan does not treat a chromosomal duplication.
- MediumEarly support
Children with the duplication may benefit from developmental, educational, and behavioral assessment.